What we prioritize first Before focusing on GLP-1 dosing terminology, we prioritize the clinical fundamentals that have the strongest relevance to cognitive longevity: blood pressure optimization ApoB, LDL, triglyceride, and lipoprotein(a) risk assessment insulin resistance and glucose-pattern evaluation visceral fat and body-composition measurement resistance training and aerobic fitness sleep quality and sleep apnea evaluation when appropriate hearing and vision support nutrition quality and protein adequacy alcohol moderation inflammation and immune-metabolic context hormone evaluation when clinically indicated social connection, cognitive engagement, and meaningful activity None of these interventions is glamorous by itself
Do not estimate
It should also be noted that, from a methodological perspective, the model used (Cox with stratification by cardiovascular risk class of the trials, i.e., SURPASS-4: high risk, and all others: low risk) requires various assumptions, including the homogeneity of the relative effect of tirzepatide treatment on MACE regardless of the baseline cardiovascular risk level of the patients
[7] However, the use of GLP-1 agonists during pregnancy and lactation is less well understood, as these groups are typically excluded from clinical trials
GLP-1 receptor agonists are not recommended during pregnancy or breastfeeding
Ideal for those on prescription GLP-1 medications or looking for a natural alternative
